Navigation Links
Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
Date:10/5/2007

BOTHELL, Wash., Oct. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), a leader in molecular-biology based drug delivery technology, announced today the establishment of the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery, and its first recipients, Dr. Robert S. Langer of the Massachusetts Institute of Technology and Dr. Paul H. Johnson of Nastech.

"Cutting edge drug delivery technologies are critical to the development and success of new and better medicines that improve health care and make a profound difference in the quality of life for millions of patients. In establishing the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery, we seek to create greater awareness and appreciation of the critical role drug delivery plays in the development of improved therapeutics and to help raise awareness of drug delivery as an exciting, high-value area of expanding opportunities," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech.

Dr. Quay continued, "The recipients of the first-ever Jeffrey Wenig Memorial Award, Drs. Robert Langer and Paul Johnson, have made significant contributions to advancing the science of drug delivery and development of new therapeutics over many years of service. We are grateful to Drs. Langer and Johnson for their dedication and efforts in this field."

The Jeffrey Wenig Memorial Award is named for Dr. Jeffrey Wenig, the founder and first Chief Executive Officer of Nastech, who contributed to the development of drug delivery technologies and formed the foundation of Nastech Pharmaceutical Company. The first Jeffrey Wenig Memorial Award is sponsored, and recipients were selected, by Nastech to recognize two outstanding individuals for their leadership in advancing the development of new therapeutics through better drug delivery. Nastech plans to sponsor awards on a biennial basis and intends to partner with a leading scientific organization for future awards.

Dr. Robert Langer, Institute Professor at MIT, is widely recognized as a leader in the field of drug delivery. In 2007, he received the 2006 United States National Medal of Science. A major focus of his work is the study and development of polymers to deliver drugs, particularly proteins, DNA and RNAi. He has been involved in developing numerous companies in the field through his innovations in drug delivery and by providing expert guidance to companies as they advance novel technologies and therapeutics. Dr. Langer's patents have been licensed or sublicensed to over 180 pharmaceutical, chemical, biotechnology and medical device companies.

Dr. Paul Johnson has served as Nastech's Chief Scientific Officer since 2003. Dr. Johnson led the development of innovative technologies for non- invasive delivery of peptide and protein therapeutics. He has also been instrumental in creating solutions to barriers in the development and delivery of RNAi therapeutics. Prior to Nastech, Dr. Johnson worked as the Head of the Cell and Molecular Biology Department in the Cancer Research Department at Berlex Biosciences, the U.S. Research and Development Center for Schering AG. Dr. Johnson is retiring from Nastech effective October 5, 2007.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

Nastech Forward Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contacts:

Nastech

Ed Bell Director, Investor Relations

(425) 908-3639,

ir@nastech.com

Russo Partners, LLC

Matthew Haines (Investors/Media)

(212) 845-4235


'/>"/>
SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... In honor of National Physical Fitness and Sports Month in ... their fitness journey on social media. , The foot care company, which specializes ... product voucher each week during May to one winner. , “Whether the goal is ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Over $60 ... year’s best in pet gear and toys, leading product review site for Toys, Tots, ... of Excellence Awards at their Spring Showcase at the Metropolitan Pavilion in New ...
(Date:5/2/2016)... ... May 02, 2016 , ... Further establishing itself as ... that the new WHIMZEES Variety Value Boxes were selected from over 1,000 entrants as ... Award. , WHIMZEES natural dental chews for dogs are a favorite product among ...
(Date:5/2/2016)... CA (PRWEB) , ... May 02, 2016 , ... The 2016 World Ultimate & Guts ... Ultimate Camp at Manhattan College, made the cut. The WUGC is being held in London, ... Teams won the gold in the men’s division, another gold in the women’s masters division, ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Sixth Annual Lifestyle ... the Bellagio Hotel in Las Vegas, NV from October 17–19, 2016. The ... the event. , This year’s conference will offer presentations featuring new treatment ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... April 28, 2016 Dr. Vivek ... and Ste phen Schmidt ... a leading provider of cloud-based software solutions for life sciences, today ... to bring a wealth of insight to a growing business.  This ... George Phillips joined ArisGlobal in the position ...
(Date:4/28/2016)... FREMONT, Calif. , April 28, 2016 ... Enterprise Validation Lifecycle Management Solutions (VLMS) today ... products and services for sufferers of chronic ... management System to manage their corporate validation ... been seeking a software solution to manage ...
Breaking Medicine Technology: